Roanoke Asset Management Corp NY raised its position in shares of BioScrip, Inc. (NASDAQ:BIOS) by 72.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 403,280 shares of the company’s stock after buying an additional 170,000 shares during the period. Roanoke Asset Management Corp NY’s holdings in BioScrip were worth $1,095,000 as of its most recent filing with the SEC.
A number of other hedge funds have also bought and sold shares of BIOS. Sheets Smith Wealth Management increased its stake in BioScrip by 13.4% in the second quarter. Sheets Smith Wealth Management now owns 125,328 shares of the company’s stock worth $340,000 after buying an additional 14,820 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in BioScrip by 65.8% in the first quarter. Goldman Sachs Group Inc. now owns 64,257 shares of the company’s stock worth $109,000 after buying an additional 25,500 shares in the last quarter. Wynnefield Capital Inc. increased its stake in BioScrip by 2.7% in the first quarter. Wynnefield Capital Inc. now owns 3,800,000 shares of the company’s stock worth $6,460,000 after buying an additional 100,000 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in BioScrip by 5.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 488,076 shares of the company’s stock worth $830,000 after buying an additional 23,598 shares in the last quarter. Finally, KCG Holdings Inc. increased its stake in BioScrip by 176.2% in the first quarter. KCG Holdings Inc. now owns 209,586 shares of the company’s stock worth $356,000 after buying an additional 133,715 shares in the last quarter. 83.06% of the stock is owned by hedge funds and other institutional investors.
BioScrip, Inc. (NASDAQ:BIOS) traded up 1.38% during mid-day trading on Friday, reaching $2.93. 632,171 shares of the company’s stock were exchanged. The company has a 50-day moving average of $2.61 and a 200-day moving average of $1.88. BioScrip, Inc. has a 52-week low of $0.98 and a 52-week high of $3.43. The stock’s market cap is $354.48 million.
BioScrip (NASDAQ:BIOS) last released its quarterly earnings data on Thursday, May 4th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.04. The firm had revenue of $217.80 million for the quarter, compared to the consensus estimate of $230.23 million. During the same period in the prior year, the business earned ($0.17) EPS. The company’s revenue for the quarter was down 8.7% compared to the same quarter last year. Equities research analysts anticipate that BioScrip, Inc. will post ($0.38) earnings per share for the current year.
A number of research firms have issued reports on BIOS. ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Zacks Investment Research raised shares of BioScrip from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a report on Wednesday, July 5th. Finally, Barrington Research boosted their price objective on shares of BioScrip to $3.50 and gave the company an “outperform” rating in a report on Monday, June 26th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $3.50.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Want to see what other hedge funds are holding BIOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioScrip, Inc. (NASDAQ:BIOS).
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
